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The integration of adaptive radiation therapy (ART), or modifying the treatment plan during the treatment course, is
becoming more widely available in clinical practice. ART offers strong potential for minimizing treatment-related toxicity
while escalating or de-escalating target doses based on the dose to organs at risk. Yet, ART workflows add complexity into
the radiation therapy planning and delivery process that may introduce additional uncertainties. This work sought to review
presently available ART workflows and technological considerations such as image quality, deformable image registration,
and dose accumulation. Quality assurance considerations for ART components and minimum recommendations are
described. Personnel and workflow efficiency recommendations are provided, as is a summary of currently available clinical
evidence supporting the implementation of ART. Finally, to guide future clinical trial protocols, an example ART physician
directive and a physics template following standard NRG Oncology protocol is provided. Ó 2020 Published by Elsevier Inc.

Introduction
Adaptive radiation therapy (ART) was introduced in the
late 1990s as “a closed loop radiation treatment process
where the treatment plan can be modified using a systematic feedback of measurements with the intention to
improve radiation treatment by systematically monitoring
treatment variations and incorporating them to reoptimize
the treatment plan early on during the course of treatment.”1 By accounting for changes in the patient’s anatomy
during the treatment course, isotoxic-based radiation therapy (escalating or de-escalating target doses to maintain a
constant, acceptable risk of clinical toxicity based on the
dose to organs at risk [OARs]) has been demonstrated.2-4
ART may be implemented to address patient-specific
treatment variations, including systematic changes in
weight, tumor, and organ geometric and biological
response, as well as stochastic variations such as organ
deformation, filling change, and respiration and peristaltic
motion. These variations may occur at different time scales
ranging from seconds to hours to days. As a result, the
implementation of ART is often binned into 3 major classes: (1) offline between treatment fractions, (2) online
immediately before a treatment fraction, and (3) real-time
during a treatment fraction, with major steps outlined in
Figure 1.
Offline ART mostly addresses systematic and progressive changes that occur during the treatment course, such as
patient weight loss and tumor morphologic changes.5 For
offline ART, adjustments to a patient’s treatment plan parameters based on these observed changes are modified
after the current treatment fraction and typically follow the
same clinical workflow as regular initial treatment planning. Repeat simulation may be required if the acquired inroom image is not sufficient for treatment planning, followed by contouring, planning, and patient-specific quality
assurance (PSQA). The resultant new treatment plan is
reviewed by the physician and then implemented in subsequent delivery sessions. Offline ART has been shown in
prospective clinical trials in the prostate, head and neck,
and lung to yield improved target coverage and OAR
sparing.2,6-9

Many treatment variations, such as interfractional target
and organ displacement, particularly in the abdomen and
pelvis, and deformation of OARs will occur during a
shorter time scale; thus, offline ART is not sufficient to
account for these variations. Online ART is a process in
which the patient’s treatment plan is adjusted before
treatment delivery to account for temporal and stochastic
changes detected in a single treatment fraction while the
patient remains in the treatment position. As a result, online
ART requires imaging, rapid replanning, plan review, and
an acceptable form of PSQA. Although resource and time
intensive, online ART has shown promise for conventional
and stereotactic body radiation therapy to enable better
OAR sparing and improved target coverage, particularly in
the head and neck,10 abdomen,11-14 and pelvis,15-18 and
more recently for ultracentral lung cancer.19 Promising data
have emerged for using daily online magnetic resonance
(MR)-guided ART for localized prostate cancer, showing a
low incidence of early gastrointestinal and genitourinary
toxicities in clinician- and patient-reported outcomes.20 A
multi-institutional prospective phase 2 study of stereotactic
MR-guided on-table ART with real-time respiratory gating
for patients with locally advanced pancreatic cancer is
currently enrolling to evaluate toxicity, overall/progressionfree survival, and patient-reported quality of life (QOL)
using daily online ART.21 Daily target dose escalation has
also been proposed when OARs are in a favorable location,
although clinical evidence is still emerging.
To account for variations that occur within a treatment
fraction, such as respiration, internal status changes, and
peristalsis motion, real-time ART has been introduced, in
which the treatment plan is automatically adapted during
treatment delivery without operator intervention. Realtime ART may be performed through treatment gating,
dynamic tracking by the treatment machine (eg, CyberKnife [Accuray, Sunnyvale, CA] or Vero22 [Brainlab,
Munich, Germany] systems), by the multileaf collimators
(MLCs), and intrafraction replanning, although such an
approach typically requires continuous imaging with
constant replanning and rapid dose calculation.23-25 The
CyberKnife Stereotactic Radiosurgery System with Synchrony Respiratory Tracking System dynamically tracks
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Typical elements in adaptive radiation therapy workflows, including online, offline, and real-time approaches.

tumors that move during respiration via an external to
internal motion correlation model updated throughout
treatment using x-ray imaging.26,27 More recently, the
Radixact (Accuray), a next-generation helical tomotherapy system, has integrated intrafraction motion management based on the Synchrony to predict motion based on
implanted fiducials or the tumor itself.28 Real-time ART
has also been realized using simultaneous intrafraction
monitoring for target identification and MLC tracking to
align the beam to the target for stereotactic body radiation
therapy (SBRT) prostate cases using a standard linear
accelerator (linac).29

In addition to classification based on the time domain,
ART may be characterized as anatomically or biologically
driven based on treatment variations. Biologically guided
ART holds great promise because changes at physiologic
and molecular levels usually occur before anatomic change,
leading to early treatment adaption. Patient-specific biological changes during treatment have been shown to
correlate with clinical outcomes and toxicity profiles, suggesting strong clinical benefits of biological-guided ART in
personalized treatment. However, biologically guided ART
remains limited in clinical practice. The majority of the
current studies focus on adjustment of target volumes based
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on functional imaging obtained during the treatment
course, with a comprehensive review of biologically guided
ART provided in the literature.30 Several ongoing clinical
trials are underway (e.g., NCT02031250, NCT03416153,
NCT03224000, and NCT01504815) that aim to investigate
functional subvolume boosting and dose scheme changes
based on functional imaging.
Regardless of the class of ART implementation or
combinations thereof, the increasing interest in ART along
with emerging vendor-provided products and workflows
will undoubtedly increase ART utilization. Yet, ART introduces complexities into the clinical workflow that will
necessitate rigorous benchmarking and evaluation. This
need will become even greater as ART is applied to clinical
trials, in which safe and consistent implementation is of
paramount importance to ensure high fidelity in trial outcomes. Overall, this work describes considerations pertinent to the implementation of ART techniques and
establishes a foundation for the safe and effective implementation of ART both in conventional clinical contexts
and in clinical trials.

Technological Considerations for ART
Image acquisition
Performing the necessary steps for ART requires adequate
information for tumor/OAR delineation, accurate dose
calculation, and sufficient image quality. Table 1 summarizes the major imaging modalities used in different
ART workflows at the present time, their advantages and
disadvantages, and special considerations for their
implementation, accompanied by a consensus subjective
grading system for the merits of each modality. Although
Table 1 highlights the current imaging modalities being
implemented, new image reconstruction algorithms are
emerging that may have implications for ART performance, such as iterative cone beam computed tomography
(iCBCT), which has shown promise for improved image
quality and more complete fields of view (FOVs) than
conventional CBCT.31,32 Recently, Ethos (Varian, Palo
Alto, CA) was introduced; it integrates iterative CBCT for
dose calculation on the anatomy of the day, with clinical
integration efforts ongoing.33 Furthermore, with the
recent trend toward hypofractionated treatment regimens,
imaging doses are expected to become less of a concern in
the future.

Deformable image registration
Deformable image registration (DIR) is an important step
commonly used during ART to account for changes in the
shape and size of internal organs between the initial and
adaptive planning images acquired during the treatment
course. For offline ART, DIR is used as needed. The
adaptive planning image may include high-quality
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computed tomography (CT) images, images that were
used for image guided radiation therapy (IGRT) (ie, CBCT
and magnetic resonance imaging [MRI]), or an interim
functional image such as a positron emission tomography
(PET)-CT or MRI. For online ART workflows, DIR is often
used at every fraction before treatment delivery for tasks
such as deforming contours or performing electron density
mapping between the initial planning data set and the daily
images used for patient positioning. At present, many
treatment planning vendors and standalone image registration software suites offer DIR and ART workflows, as
summarized in Table 2.
Deformation vector fields (DVFs), or the voxel-by-voxel
3D transformation matrix obtained from DIR,34 are often
applied for tasks such as contour propagation, plan
adjustment, and fractional dose accumulation.23,35 Therefore, any errors introduced in the image deformation process may be propagated downstream in the ART workflow.
Error and uncertainty originating from DIR often arise from
the image quality of the 2 input images, inaccuracy of the
DIR algorithms, and any parameter selection or manual
adjustment during the registration process. For online and
offline ART, the input images include the original planning
data set (the moving image) and the stationary image acquired during treatment. It is important that both the
moving and stationary image be evaluated for image
quality because errors from the input images often arise
from image artifacts (eg, noise, blur caused by motion,
image truncation) or image distortion, such as in MRI.
In 1998, Maintz and Viergever36 summarized image
registration variables and categorized them using 9 criteria,
including dimensionality, nature of the registration basis,
domain of the transformation, degree of interaction, optimization procedure, image modalities, involved subjects,
and body sites. Twenty years later, these classifications still
hold, with minor revisions.37 All of these variables introduce various degrees of errors and uncertainties during DIR
that are convoluted in the DVF obtained from image
deformation, which will then be applied for contour mapping and dose deformation/accumulation tasks. Therefore,
it is essential for the end user to perform validation of the
DIR algorithm.
However, direct quantitative validation of DIR using the
DVF has proven difficult owing to the lack of ground truth.
Recently, AAPM Task Group 132 (TG-132) has provided
guidelines on using qualitative and quantitative measures
for evaluating image registration accuracy.34 Qualitative
methods include visual checking with various display
methods, including image-to-image comparison with or
without mapped contour/structure overlays. Quantitative
metrics include target registration error, mean distance to
agreement, the Dice similarity coefficient (DSC), Jacobian
matrix (identifying local volume changes such as expansion
or contraction that may indicate erroneous regions of interest), and consistency (or the independence of the algorithm to the direction of the registration). TG-132 has
provided expected tolerances to each of these metrics based
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Image modality considerations for online and offline ART implementations

ART imaging
modality
considerations

Diagnostic quality.
Same as planning CT scan

CBCT

Same as planning CT
scandsubmillimeter, can
be limited longitudinally

***
Same as planning CT
scandsubmillimeter,
longitudinally typically 1
mm

*****

**
Same as planning CT
scandsubmillimeter,
longitudinally typically 2
mm

****

****

Motion artifacts

Fast scan but motion must be Long scan times prone to
managed to avoid artifacts
motion artifacts

Long scan times prone to
motion artifacts

Clinical motion
management
solutions

Yes

No

Yes

****
Reconstruction
artifacts

Prone to hardening artifacts
from high Z materials or
elongated body shape,
motion
***

Geometry
Anatomy

Anatomy changes from CT,
organ localization
****

FOV limitations

MRI

**

**

*****
Similar to planning CT
scandsubmillimeter,
longitudinally typically
1 mm

Scan times can be long or
short, prone to motion
artifacts
Yes

***

Same artifacts as CT, as well Same artifacts as CT, zipper Susceptibility, motion,
artifacts
distortion
as scatter, ring, aliasing,
and misalignment artifacts

***
Anatomy changes, organ
localization
***

***
Anatomy changes, organ
localization
***

****

***

***

***
Typically few mm in each
direction PET, depends on
body site

****

**
Anatomy changes, organ
localization
*****

Up to 50 cm FOV, large FOV Up to 50 cm FOV, large FOV Up to 50 cm FOV
results in poor image
results in poor image
quality
quality

60 cm FOV

PET

Excellent soft tissue contrast No soft tissue differentiation
Good contrast for largeGood contrast for largebut provides quantitative
density differences such as density differences such as
functional information
bone/ tissue/air. Scatter
bone/ tissue/air. Scatter
significantly decreases
significantly decreases
contrast.
contrast.

****
Spatial resolution

MVCT

****

***
Very long scan times, prone
to blurring from motion
No

*
Same artifacts as CT,
attenuation correction,
motion, CT reconstruction
and partial volume
**
Metabolic uptake changes

****
Up to 70 cm FOV

****
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Table 1

Same as planning CT scan

Can affect image quality
depending on position on
treatment couch

***

Bore size may limit patient
position, coil placement
may limit use of
accessories

***

***

May not be same as
simulation setup, PET scan
bore size may limit patient
position
****

Truncated structures

Same as planning CT scan

FOV limitations may truncate FOV limitations may truncate FOV limitations may truncate Same as planning CT scan
structures
structures
structures and external
contour

Tracking organ motion

Not available during
treatment

Not available during
treatment

*
Density
HU table management

Same as planning CT scan

*
Can build custom HU
table 1%-2% accuracy in
dose calculation

*****
Online/offline ART
Modality for online

CT on rails

*****
CBCT

***
Additional dose to patient Up to 3 cGy per scan

***

Not available during
treatment
*
MVCT number, similar to
HU table, must be
monitored at high
frequency
***

Available

Not available during
treatment
****

Not available, surrogate
needed

**

Tomotherapy able to sum
MRI-cobalt, MRI-linac
plans and “dose of the day”
***

Up to 10 cGy per scan

**

***
Up to 5 cGy per scan

**

****
Not applicable

*****

*
Same as planning CT scan if
PET-CT

*****
Under development

*
Up to 3 cGy whole body plus
CT dose
**

Grading system: (least to most advantageous, 1* to 5*) based on consensus grading by authors.
Abbreviations: ART Z adaptive radiation therpy; CBCT Z cone beam computed tomography; FOV Z field of view; HU Z Hounsfield units; linac Z linear accelerator; MVCT Z megavoltage computed
tomography; MRI Z magnetic resonance imaging.
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Table 2

Summary of currently available deformable image registration and relevant adaptive radiation therapy components

Vendor

DIR algorithm

Multimodal
Unimodal
registration
Dose
registration
(CT, PET,
Contour
warping and Offline Online
(CT, CBCT)
MR)
propagation summation
ART
ART

Stand-alone DIR
products
MIM (v 6.8)
Free-form, Demons optical flow27,28
Velocity (v 3.2)
Multipass B-spline29
Mirada (v RTX1.8)
Unimodal: free-form
Multimodal: radial basis function30
Treatment planning
systems with
DIR modules
Raystation (v 9A)
ANACONDA,31 MORFEUS32
Eclipse (v 15.6)

Unimodal: accelerated Demons33
Multimodal: adaptive grid-based radial
basis function

Yes
Yes
Yes

Yes
Yes
Yes

Yes
Yes
Yes

Yes
Yes
Yes

No
Yes*
Yes*

No
No
No

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

No

Pinnacle (v 9.10)

Fast symmetrical Demons, salientfeatureebased registration34,35

Yes

Yes

Yes

Yes

No

No

Monaco (v 5.51)

Gradient-free dense hybrid MI
deformation36,37

Yes

Yes

Yes

Yes

Yes

Yes

Precision (v 2.1)

Multiorgan B-spline38

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

ViewRay (v 5.2.5)

Free-form
Unimodal: correlation coefficient
Multimodal: mutual information

Abbreviations: ANACONDA Z ANAtomically CONstrained Deformation Algorithm; ART Z adaptive radiation therapy; CBCT Z cone beam
computed tomography; CT Z computed tomography; DIR Z deformable image registration; MI Z mutual information; MORFEUS Z multiorgan finite
element modeling algorithm; MR Z magnetic resonance; PET Z positron emission tomography.
* Partial offline ART functionality (no treatment planning).

on the application and image voxel dimensions. Validation
of DIR performance often consists of verifying landmarks
such as bifurcations or implanted markers.38 In addition,
subjective scoring methods for evaluating the mapped
structures have been proposed.39,40 Phantom data sets for
multiple modalities (ie, CT, CBCT, PET, and MRI) have
been made available by TG-132 for DIR validation and are
currently under evaluation by the NRG Image Deformation
Working Group. Publicly available data sets have also been
created for image registration validation, including brain
MR images,41 head and neck CT images,42 prostate CT
images,43 and thoracic CT and 4DCT images,43-46 to
benchmark DIR performance.

Dose accumulation and tracking
ART may yield significant improvements in accommodating tumor and OAR changes during the treatment course
when the original planning data set is not fully representative of the anatomy of the day. However, as the anatomy

and corresponding contours change, the initial dose calculated by using the planning data set may have limited accuracy and may not continue to represent the actual
delivered dose. For example, in a head and neck cohort of
13 patients, a dose reduction of 0.2 to 7.4 Gy was observed
in the planning target volume (PTV) coverage (D95%) with
increased maximum doses of 0.6 to 8.1 Gy and 0.2 to 15.4
Gy in the brain stem and cord, respectively.47 Recently,
MR-guided ART has shown that for pancreas SBRT, the
dose to the duodenal loop would increase by up to 6 Gy
whereas the PTV coverage would be reduced by up to 4.5%
if the plan were not adapted.48 Therefore, ART calls for an
updated 3D data set representing the current anatomy, an
adaptive plan tailored to the anatomy change, and, ideally,
an accurate summary of the “as delivered” dose. Here, “as
delivered” refers to updated dose reporting that takes into
account tumor and adjacent OAR anatomy changes, with a
determined dose (dose-volume histogram) that was delivered to the patient. To provide such an updated delivered
dose, a voxel-by-voxel dose accumulation for each delivery
timepoint needs to be determined by deforming the dose
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based on the calculated DVF from DIR over the treatment
course with the dose warped back to the initial planning CT
for dose accumulation for the total fractions to date.49
An alternative approach to obtain the daily delivered
dose is to deform the initial planning data set to match the
daily IGRT image (ie, CBCT, megavoltage computed tomography, CT on rails, or MRI) for calculating the “dose of
the day.” By applying DIR, the dose calculated based on a
deformed planning CT has been shown have 95% of the
voxels agree at 2 mm/2% with the resimulated CT dose,50
which may be considered clinically acceptable. This
methodology of deforming the adapted planning image
yields improved dose estimation compared with conventional dose calculations based on the rigid registration of
the planning CT or directly on the CBCT itself.
Nevertheless, estimating the cumulative dose is still
highly dependent on the choice of DIR algorithm and the
underlying image quality. For online ART, ideally, a fully
integrated treatment planning, imaging, and dose delivery
system accompanied by an optimized DIR algorithm would
be needed to implement this computationally intense
adaptive workflow in an efficient fashion. The calculated
“dose of the day” for each fraction can be warped back to
the reference CT (ie, the planning CT) or MRI data set and
summed to obtain the estimated accumulated dose. The
accuracy of this accumulated dose is highly dependent on
the DVF generated from the initial steps of image deformation. A wide range of DIR accuracy has been reported,
from <1 mm up to 10 mm depending on the disease site
and DIR algorithm used.41,43,51 Corresponding dose deviations illuminated via accumulation may have clinical
impact, depending on the cancer site, image modality and
quality, DIR algorithm, parameter choices, dose evaluation
metrics (eg, mean, maximum, minimum, D95), organ volume/motion, and other factors.52-55
The accuracy of dose warping and accumulation depends on the accuracy of the DVF, which may be limited by
internal target changes (ie, shrinkage or growth) and
movement of the adjacent organs that may challenge
boundary detection. Mass changes are a particular challenge for DIR, and other methods to accommodate them,
such as integrating models of tumor regression,56 have been
described in the literature. To date, limited studies provide
reliable quality assurance (QA) methods to ensure the accuracy of dose warping and accumulation for patient data
sets; thus, caution must be taken when applying to ART
decision-making.

Rapid replanning
Replanning cases for ART involves consideration of the
strategy (offline vs online), timely delineation of targets
and/or OARs, the time it takes to replan, and the clinical
criteria as to what necessitates the adaptation. RTOG 1106
is an example of an offline ART clinical trial schema for
advanced stage lung cancer in which the experimental arm
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includes a PET/CT and CT resimulation acquired after
fraction 18, offline replanning, and a new treatment plan
beginning on fraction 22 to allow sufficient time for the
development and QA of the adapted plan.57 A recently
published offline ART protocol for oropharynx cancer
included weekly adaptation using geometric criteria (when
the gross tumor volume [GTV] shrinkage exceeded 2 mm)
via CT and MR simulation data acquired at intervals of 5 
2 fractions.58 An offline adaptive scheme using CBCTgenerated contours from the initial 6 fractions of radiation therapy for prostate cancer has been used to generate
average positions of the CTV and rectum, with w7  0.5
hours additional time needed to perform the additional
replanning.59 Offline ART workflow solutions are
becoming commercially available to help in the decisionmaking process regarding adaptation. For example, Accuray’s PreciseART treatment planning system allows for
automated dose monitoring and volume-based statistics that
may be reviewed offline to assess the need for adaptation,
with example cases taking 2 to 8 fractions between plan
evaluation and treating with a new adapted plan.60 The total
time required for offline ART will depend on several factors, including the amount of multimodality imaging
needed, total number of organs that need to be recontoured,
dose accumulation/plan evaluation, PSQA if warranted, and
any treatment planning dose constraint challenges that may
be introduced.
To facilitate online ART, contours required for replanning must be generated rapidly while the patient is on the
treatment table. Strategies to expedite recontouring have
included implementing rigid or DIR to propagate delineated volumes from the initial simulation images or previous fractions to the daily image. Another strategy is to
perform manual recontouring limited to regions in close
proximity to the target volume, such as in an MR-guided
online ART scenario in the abdomen where only the OARs
within a 3-cm expansion of the PTV are delineated.61,62 The
rationale for using a subset of the OAR volume is that OAR
dose tolerances are often expressed as a small-volume dose
constraint (typically D0.5cc), and presumably these will be
located close to the target volume. Recent results presented
for MR-guided online ART showed clinically acceptable
contouring times (median, 9 minutes; range, 2-24 minutes)
to allow for daily adaptation in a clinical trial setting using
this contouring strategy.11 Recent efforts using rapid autocontouring approaches such as deep learning63,64 are
emerging and offer great potential to facilitate more efficient online ART. One such example is Varian’s Ethos
online x-rayebased ART solution that uses neural networks
involving a large library of images and ground truth contours to autosegment the anatomy of the day.33
Aside from recontouring, plan reoptimization must also
be performed quickly for online ART. For head and neck
cancer cases using CT on rails and a conventional linac, an
online ART workflow for plan reoptimization can be
completed in 5 to 8 minutes.10 To perform a more expedited
optimization, one strategy includes combining all OARs
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into a single optimization structure to decrease the total
objectives that need to be achieved by the optimizer and
thereby simplify the optimization process. This also makes
for a more robust planning approach because the achieved
dose distribution will be less sensitive to expected daily
changes, although caution must be exercised to ensure all
necessary OARs are included in the optimization. Sophisticated workflows for online optimization have been
implemented, including using an artificial neural network
that provided robust parameters that consistently met the
OAR constraints, compared with a failure rate of 36% of
fractions in which a conventional optimization approach
was used.62 Reoptimization times ranging from 10 to 223
seconds for full reoptimization of lumbar spine bone metastases have been achieved on a 1.5T MR linac.65
To ensure accurate dose calculation, an accurate CT
number (and, hence, electron density) is required. In an
MR-guided ART workflow, multimodality DIRs between
the CT, daily electron density map, and MRI may severely
warp the images, as shown in Figure 2, and introduce uncertainties in dose calculation. This also requires substantial personnel effort to fix the underlying electron density
map via manual overrides of air and tissue. Indeed, the
evaluation and correction of electron density maps is a ratelimiting QA step requiring significant resources in many
MR-only and ART workflows,66-68 and thus appropriate QA
steps are required to address these uncertainties during
online replanning.
Overall, performing the entire online MR-guided ART
process including IGRT, recontouring, replanning, and QA
has been reported to have a median on-table time of w80
minutes per fraction (range, 36-160 minutes) for abdominal
malignancies11 and 45 minutes (40-70 minutes) for prostate

SBRT (typically 7.25 Gy/fraction).66 For high-field MRguided ART of abdominal SBRT using 4D-MRI guidance,
the median overall total treatment was w62 minutes using
an adapt-to-shape workflow.69 For an online adapt-to-shape
prostate SBRT (35 Gy/5 fraction) workflow, a median
fraction treatment time of 50 minutes (range, 46-65) has
been reported.70

Pretreatment plan and delivery QA
Offline ART strategies follow treatment planning and
delivery QA procedures that are standard of practice.
Online ART, on the other hand, requires plan and delivery
checks to be performed in an accelerated timeframe. At
present, commercially available options are limited; thus,
many groups are developing in-house QA tools. One such
example is for MR-guided ART in which a software
program reads DICOM data from the base and daily
adapted plan and compares the beam angles, number of
segments, beam-on time, fluence patterns, and volumes
(initial vs replanned).71 An independent secondary dose
calculation was also developed to ensure the adapted
plan’s integrity before treatment. Another in-house QA
tool built in Cþþ can be used for conventional and MRguided linacs and checks demographics, imaging information (ie, patient orientation, electron density), contour
integrity, monitor units, MLCs and jaws within machine
specifications, and dose calculation accuracy.72 The
MRIdian Linac (ViewRay Inc, Mountain View, CA) has a
vendor-provided online adaptive QA tool that runs on the
treatment console and performs a rapid secondary dose
calculation of the new adapted treatment plan. A report is
automatically generated with plan comparisons, 3D

Fig. 2. Deformable image registration is used in many aspects of the adaptive radiation therapy (ART) workflow, including
contour propagation and density redistribution. Note the deformed right kidney and erroneously warped deformed density
map highlighting the need for per-fraction review and quality assurance of the electron density map and contours used for
online ART. Abbreviations: LT Z left; PTV Z planning target volume; RT Z right.
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gamma analysis, contour/dose statistics, and per-beam
fluence comparisons. ART workflows may integrate
third-party independent dose calculation and adaptive
plan QA, such as the Varian Ethos system that uses the
Mobius QA platform.33 Other commercial options are
emerging or are being customized that provide independent dose calculation checks, such as MU2Net and RadCalc. Ideally, automated plan checks and secondary dose
calculation tools would perform an independent evaluation of plan quality; however, these are still works in
progress for many vendors and remain an unmet need.

Dose reporting
A methodology for dose reporting is also required to ensure
homogeneity across clinical trial study sites. For example,
the protocol could state that full OAR delineation is
required (whether in real time or postdelivery) or that a
more limited delineation scheme (ie, a few centimeters
from the PTV) can be performed to facilitate more rapid
contouring for online dose evaluation and subsequently
reviewed offline with full delineations. An alternative
strategy would be to implement concepts from brachytherapy, as carried out in NRG-GY006.73 Here, volume
dose parameters are defined for dose tracking and reporting
per ICRU Report #89.74 In GY006, the specific reference
point locations and volume definitions are well defined (ie,
D2cc of the bladder, rectum, and sigmoid) and are recorded
for each fraction.73

Quality Assurance Needs
Deformable image registration and contour
propagation benchmarking
Direct qualitative evaluation of a DIR result can be performed via what TG-132 defines as an image-image visual
validation of the deformed image with respect to the stationary image, including split screen displays, region of
interest overlap, overlay assessment, or side-by-side display
via a linked cursor.34 Many commercially available software packages include functionality to visually display
DVFs that can be overlaid on the deformed data set,
including incorporating color coding and vector length
displays to highlight potential regions of nonphysical or
erroneous deformations. Although TG-132 recommends
that DIR programs be able to export a DVF in DICOM
format, vendor compliance is still a work in progress.
Nevertheless, to properly perform a quantitative benchmarking of DIR accuracy, appropriate physical or digital
phantoms are required. Although deformable physical
phantoms with implanted landmarks have been built, at
present they are not widely commercially available.75-77
Benchmarking multimodality ART workflows such as
MRI/CT or PET-CT/CT with physical phantoms also introduces challenges in phantom construction and landmark
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visibility. The major advantage of using physical phantoms
is to perform end-to-end testing in a clinical setting with
consideration of the entire ART workflow. However, more
straightforward DIR benchmarking can be achieved via the
use of a digital phantom for comparing a user-obtained
DVF generated by the DIR software with a gold-standard
DVF. A digital validation set can be created in software
from virtual phantoms or patient scans by generating a
warped image and its associated structure set from an
original image (and its associated structure set) with a
known DVF.78 Ideally, the original image and structure set,
warped image and structure set, and ground-truth DVFs can
all be imported to a user’s DIR software for testing. Several
studies have explored this approach,51,79 and TG-132 also
provided data sets created from ImSimQA software and
recommended commercial DIR software vendors to provide feasible tools for user validation.80 TG-132 provides
guidelines for DIR evaluation metrics such as setting the
tolerance of point-wise registration error or mean distance
to agreement between 2 surfaces to within the magnitude of
the maximum voxel dimension (approximately 2-3 mm).
Yet, few commercial systems adopted by radiation
oncology departments have the recommended function for
importing or comparing DVF files. In this case, indirect
validation metrics (eg, target registration error, DSC, mean
distance to agreement) may have to be adopted for clinically feasible evaluation of DIR quality comparing propagated landmarks and structures with the ground truth.34,80 A
detailed multi-institution evaluation of DIR commissioning
and QA is currently underway by NRG Oncology to provide benchmarking guidelines for clinical trials involving
DIR and ART. The testing criteria include TG-132
compliance, rigid registration accuracy, and deformable
registration accuracy between the planning CT and other
image modalities (CT, CBCT, PET, and MRI) for various
body sites including head and neck, lung, and prostate.
Autosegmentation may also be part of an ART workflow.
These contours, whether created de novo or through DIR
contour propagation, should be reviewed by a radiation
oncologist or other appropriately trained personnel. A ratelimiting step in the process may be reliance on a physician
to recontour the relevant OARs or target. Opportunities to
make this more efficient include workflows that enable safe
remote contouring and viewing,81 training therapists or
other auxiliary staff to perform the initial recontouring with
physician approval,82 and systematic applications of autocontouring tools. Evaluation of the autocontouring functionality should be assessed before clinical implementation,
and a protocol for the review of contours generated during
online ART should be established. Ultimately, the accuracy
of the final contours should be within the uncertainty of an
expert contouring the structure from scratch, with a tolerance for the DSC value between 2 contours to be within the
contouring uncertainty (approximately 0.8-0.9).34 Generally speaking, many online ART workflows consist of
rigidly copying the target volumes to the daily image in lieu
of deforming or modifying the target during the online
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process.11 The clinical rationale for this decision is that
complementary, multimodality diagnostic images as well as
consultation of surgical or diagnostic reports are often used
to assist in target delineation but are not typically available
at the time of online replanning. For example, in a prospective clinical trial for prostate SBRT, the prostate target
volume was rigidly registered to the anatomy of the day and
only edited as needed, such as with rotational differences.62
Dose accumulation may be used for retrospective evaluation of the delivered dose, with the verification carrying
particular significance when plans are created based on
images other than a conventional simulation CT (eg, dose
based on a CBCT or a synthetic CT generated from MRI).
Dose accumulation accuracy depends on the DIR accuracy
as well as mass changes occurring during the treatment
course.83 Efforts are currently underway to further develop
validation schemes, such as developing new methods for
dose mapping,84 using the energy conservation criterion,85
developing uncertainty metrics,86 and using computational78 or deformable phantoms.87,88

involved in an ART workflow, the final dosimetric accuracy should be within the conventional guideline of 5%
of the intended dose.5
At present, only a few physical phantoms have been
made by independent investigators to meet all these needs.
Multimodality anthropomorphic pelvis phantoms that
mimic internal organ kinematics have been built
recently.88,90 Deformable lung91 and abdominal phantoms75,92 have also been devised and have been implemented to evaluate accumulated dose. In addition to end-toend tests to verify the planning and delivery of an ART
workflow, failure mode effects analysis may be used to
characterize the ART process and to further direct efforts of
the associated QA program, such as described for realtime93 and online94 ART.

Machine-specific quality assurance
As is the case with non-ART workflows, the treatment
machine needs to perform within specifications for reliable
radiation delivery. For conventional mechanical and dosimetric assessment of machine performance, a standard QA
program as described in AAPM Task Group Reports 142 is
appropriate.89 ART features an increased dependence on
imaging systems in the treatment room. This underscores
the need for appropriate periodic QA regarding image
quality. Robust examination of factors such as geometric
distortion, image artifacts, and HU-to-electron density
calibration curves is necessary if the imaging system is to
be used for ART replanning.

End-to-end testing of ART workflows
An end-to-end verification test should be conducted
before clinical implementation of ART to evaluate the
system holistically and to establish confidence in the dose
delivered to the patient. To benchmark offline ART, digital phantoms such as the TG-132 test suite or POPI
model can be implemented to benchmark DIR and dose
accumulation depending on the imaging modality used in
the workflow. For online ART, end-to-end verification
should include the imaging of at least 2 geometries of a
physical phantom using the modalities used in the ART
workflow (eg, CT, CBCT, MRI), the clinical use of ART
subsystems (eg, DIR, autocontouring, dose accumulation,
and plan reoptimization), and ultimately, the comparison
of cumulative delivered dose with the intended dose
modeled by the treatment planning system. A verification
of the secondary dose calculation or verification system
should also be performed using the modified geometry.
Regardless of the additional tasks and subsystems

Adaptive plan-specific quality assurance
For online ART, PSQA options may be limited before
treatment delivery. Performing measurements on each plan
can become impractical if additional plans are created
frequently, and predelivery measurements may not be
feasible for online workflows when the patient is on the
table.95 As a result, one must balance the practical costs of
plan-specific QA while ensuring the dose delivered is safe
and appropriate. In vivo portal dosimetry allows for patientspecific or transmission measurements that have been
applied in several ART scenarios, including using an
electronic portal imager integrated into a 1.5T MR-linac.96
Reoptimization methods such as implementing MLC
aperture morphing from a base plan as opposed to a fully
generated reoptimization may lessen the likelihood of a
PSQA failure. Finally, clinical trial endpoints (eg, dose that
causes a specific toxicity) may need to consider the possibility that protocols will adopt limited manual recontouring
of OARs within some distance of the PTV.
Generally speaking, adaptive plans should be held to a
standard with prescribed clinical criteria similar to those
in the original plan. AAPM Task Group Report 218 discusses techniques for plan-specific intensity modulated
radiation therapy (IMRT) QA and recommends tolerance
limits and action limits of 95% and 90% g passing rates,
respectively, for 3%(global)/2 mm, with a 10% dose
threshold for both the perpendicular field-by-field and true
composite methods.6 Another approach receiving
increased attention is to simulate rather than measure the
delivered dose. For offline workflows, machine log files
generated during QA delivery of the plan with or without
a phantom can be used.7,8 For online workflows, it may be
possible to perform a dry run, in which the mechanical
components of the delivery are enacted but no dose is
delivered. This could be performed with the patient on the
table, but with obvious caveats regarding added time and
risk. Lastly, for online workflows, various systems could
be used to monitor the delivered dose in real time in lieu
of pretreatment QA. Machine log files can be used in this
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way, retrospectively determining the fidelity of the
delivered plan.7 Additionally, transmission detectors
attached to the treatment machine or portal imaging devices may verify treatment field apertures and instantaneous output during delivery.
Although various PSQA methods are available, it remains imperative that rigorous plan-specific checks be
performed before treatment, including verification of plan
data integrity and plan dosimetric quality, monitoring of
unit calculations, and correct data transfer from the treatment planning system to the record and verify system.9
Software solutions are likely to play an increasing role in
verifying consistent treatment parameters and accurate data
transfer in the accelerated ART workflow.10 Where feasible,
QA on the deliverability of the treatment plan should be
conducted before the patient’s treatment. This applies to
offline ART plans and to the initial treatment plan for both
online ART and offline ART. Posttreatment analysis of the
delivered parameters will suffice where pretreatment measurements are not feasible (eg, adapted online ART plans),
provided the other checks on plan integrity and data
transfer have been performed properly.9,11

ART action levels and evaluation criteria
Clear ART directives are required a priori to facilitate both
online or offline ART in a systematic fashion. For offline
ART, directives may be based on empirical data (ie, at set
time points for replanning) or practical clinical considerations (eg, weight loss, tumor volume changes, review of
anatomic changes in daily setup images, treatment breaks,
or ill-fitting immobilization devices). Example online ART
objectives may include violations of predetermined OAR
dose limits or target dose coverage considerations, although
it is important to note that these should be evaluated using
the dose expected on the geometry and delineated organs of
the day.
Daily planning objectives will often be similar to those
used for generation of the initial plan and, whenever
possible, should be prespecified and imported into the
treatment planning system to minimize time required for
adaptive plan generation.
To facilitate routine practice of offline ART, an automated dose-volume evaluation based on the daily treatment
fraction would be ideal. The PreciseART tool (Accuray) is
a semiautomated tool that initiates the dose-volume evaluation process as soon as each fraction delivery is
completed.60 The tool automatically creates the merged
daily and plan images, deforms the plan contours, calculates dose on the daily image, accumulates the daily dose
onto the planning CT, and generates a structured report with
dose-volume data, user-defined metrics, flags, trends, and
triggers for ART. The plan reviewer can thus identify at a
glance whether a particular dose-volume objective is no
longer being met and if an adaptive plan is needed based on
a predefined action level for future fractions.
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For online ART, a solution to automatically and objectively determine when online ART is required immediately
after the acquisition of the daily image is highly desirable.
For example, Lim et al reported a method to rapidly
determine the need for online ART by analyzing the Jacobian determinant histogram obtained from the DIR between the plan and daily images without time-consuming
and labor-intensive structure delineation based on the daily
image.97 The recently introduced iterative CBCT-based
online ART platform incorporates guided clinical
decision-making at several steps in the ART process,
including image approval, autocontouring, and plan
approval.33 It is anticipated that rapid evaluation solutions
will be an active area of development.

Summary of minimum requirements and
recommendations
Table 3 provides a summary of minimum elements and QA
requirements to integrate ART into clinical trials, with
associated rationale provided for potential clinical impact.
Currently, the most comprehensive benchmarking of
ART was that implemented by the Trans Tasman Radiation Oncology Group for a multi-institutional clinical trial
of ART for bladder cancer.98 The ART schema consisted
of delivery of a conventional plan for the first 7 days of
treatment, with the remainder of the treatment delivered
using 1 of 3 plan options with varied bladder-filling
conditions. The 3 different plans were generated based
on a hybrid of the original planning CT and 5 CBCT
bladder volumes acquired during the first week of treatment. Credentialing consisted of the following: (1) a facility questionnaire, (2) a treatment planning exercise, and
(3) a site visit, including a phantom-based implementation
of image guidance. For clinical treatments, the presence
of a trained team member was required during daily IGRT.
The training of this individual consisted of a 1-day course
or an e-Learning module. The treatment planning exercise
included the delineation of structures and the generation
of plans with varied treatment planning margins based on
the union of contours generated from several treatment
fractions. Of interest is the on-site visit by trial coordinators, which included discussions, lectures, review of
the planning exercise, and past clinical CBCT data sets, as
well as a mimicked ART workflow procedure. Here,
treatment planning was conducted on digital phantom
data with an initial bladder-filling condition, and IGRT
and ART plan selection were performed based on
differing anatomy. Dosimetric verification with thermoluminescent dosimeters was also conducted.
Another such example of multi-institutional implementation and credentialing for ART clinical trials is the
Radiotherapy Trials Quality Assurance group, which has
coordinated efforts across 10 centers and 71 radiation
therapists in the United Kingdom.99 Here, real patient data
were used for credentialling, including contouring,
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Table 3

Summary of minimum requirements to consider for ART workflow components

ART component
Imaging

Element
HU accuracy

Suggested minimum requirement
CT number accuracy within 10%

1 mm (within 10 cm radial
distance of isocenter)
2 mm (>10 cm radial distance
away from isocenter)95
Low contrast resolution Per AAPM TG recommendations
for the ART planning modality
Consistent physiological Motion managed within TG-76
recommendations (<5 mm)96
state as reference
data set (breath-hold/
internal filling)
FOV
Contains all relevant anatomy and
full integrity skin contour
Geometric integrity

Potential clinical impact
20% variation in HU value may result in a
systematic dose error of 1.5%94
Inaccurate localization of organs
Inaccuracies in dose calculation
Limited boundary detection that may adversely
affect accurate delineation
Over-/underestimate of target/OAR doses
Incorrect state of internal anatomy for treatment
planning

Inaccurate dose calculation for missing anatomy
Lack of one-to-one correspondence may lead to
erroneous deformable image registration
Artifacts
ART planning image shall be free May obscure relevant anatomy
of artifacts in the clinically
Delineation accuracy adversely affected
usable FOV
Dose calculation may be adversely affected
Image registration
Deformable registration Visual assessment
Erroneous deformations may warp images,
Point-wise registration error or
leading to inaccurate geometry and
mean distance to agreement
underlying electron densities
within magnitude of maximum
voxel dimension39
Contour propagation
Visual assessment
Inaccurate dose evaluation due to incorrect
Dice similarity coefficient >0.839
target volumes
Under- or overestimated volumes
Data integrity verified via TG-5397 Localization uncertainties
End-to-end/workflow Localization using
Input/output discrepancies
testing
clinically applicable Concordance of external laser
Systematic offsets introduced
ART workflows and
system/landmarks:
imaging modalities
Preferred: 1 mm
Acceptable: 2 mm
Dosimetric accuracy
5% of intended dose5
Inaccurate dose evaluation
Abbreviations: ART Z adaptive radiation therapy; CT Z computed tomography; FOV Z field of view; HU Z Hounsfield unit; OAR Z organ at risk.

treatment planning, IGRT, the plan selection process, and
rapid review of the first enrolled patient. Overall, the credentialing process tested the main components of the trial
ART workflow, including hardware and software, and
included the decision-making process. This broad benchmarking underscores the fact that ART is dependent not
only technology but also on workflow and procedure. For
that reason, both preimplementation and periodic QA need
to evaluate the technique from a comprehensive
perspective.

Personnel Recommendations
Online ART physician directive and approval
Regardless of ART approach, the attending physicians must
first specify quantitative adaptation criteria based on a
physician directive to determine the necessity of adaptive
replanning. Typical components include the structures to be
recontoured, OAR volumetric constraints, and minimum

target coverage criteria subject to the OAR constraints. If
all OAR constraints are met owing to favorable geometry,
another ART action criterion may be target coverage
improvement above a certain threshold, such as >10%,
compared with the original plan.
When online ART is anticipated, substantial physician
involvement may be required and analogous to that
required for nonadaptive or offline treatment planning, but
with increased time constraints for online ART. For online
ART, physician approval may be required for patient
localization and positioning, which is analogous to
approval of simulation in the offline setting. Subsequent
delineation and thorough review of target and OAR segmentation are required to evaluate the need for online
adaptation and facilitate plan reoptimization if clinically
indicated. Similar to offline ART processes, review and
approval are required for target and OAR segmentation
before replanning, with objectives provided for target
coverage and OAR sparing.
Although physicians often participate in this process,
recent efforts have been implemented to train radiation
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therapists or other staff members to perform contouring.81
Ultimately, if a new plan is found to be justified based on
predefined clinical criteria, documented physician approval
of the new plan and associated QA is required to confirm
the adapted prescribed dose, volume, and technique and to
document any planned escalation or de-escalation in the
prescribed target dose based on the patient anatomy of the
day. In the context of clinical trial implementation, the
physician directive should also include the objective indication for ART to generate data regarding prevalence of
specific ART indications.

Online ART tasks and responsibilities
An online ART workflow can be best described as a choreographed process involving contributions from several
team members, including radiation therapists, medical
physicists, and physicians, with typical roles as outlined in
Table 4. An example low-field online MRgART workflow is
described because it has been previously published in
several clinical trials,11,20,48 with similar workflows also
being reported for high-field MRgART.100
First, the radiation therapists bring the patient into the
room, perform initial setup, and acquire a volumetric MRI
suitable for target alignment and with a large enough FOV
to facilitate online treatment planning. The radiation therapist then aligns the treatment target in the image guided
radiation therapy workspace and pages the covering
physician and adaptive planner (typically a physicist or
dosimetrist). Deformable registrationebased autosegmentation is initiated, followed by manual edits of
autogenerated critical structure contours. Critical structure
contours may be edited by the adaptive planner and may be
reviewed by the covering physician or other qualified
personnel. The gross tumor volume is rigidly propagated
(not deformed) and may be edited by the covering physician as deemed necessary. Derived structures, such as PTV
expansions or optimization volumes, are generated based

Table 4

on predetermined workflows that can be rapidly applied
online. Dose is then recalculated on an electron density data
set derived from registration of the initial plan’s electron
density to the daily setup image. The “predicted dose,” or
the dose that would have been delivered if the plan were not
adapted, is then evaluated using dose-volume histograms
based on the new anatomy and recontoured structures.
Based on the predicted dose, the current anatomy visualized in the setup image, and predetermined clinical criteria,
a decision is made whether to treat as-is or to adapt.
Attending physicians specify quantitative adaption
criteria per plan based on a physician-directive planning
sheet that are then used to determine the necessity of
adaptive replanning. If the decision is made to adapt, in one
example online workflow, IMRT optimization is performed
with the same structure weights and beam angles as the
offline plan (only the structures themselves, and the electron density map, having changed). Beam angles and
structure weights can be edited if needed, but they usually
are not edited because of the corresponding increase in time
required. Dosimetry of the adaptive plan is evaluated and a
decision is made whether to treat the adaptive plan, treat the
initial plan, or abort the fraction. Finally, gating parameters
are set, if applicable, and the treatment is initiated.

Offline ART physician directive and approval
Offline ART is often triggered by clinical observations such
as loose-fitting masks, patient weight loss, or changes
observed over time on volumetric on-board imaging such as
CBCT. One such example is highlighted in Figure 3 for a
patient with stage III cT3N2cM0 nasopharyngeal carcinoma who was scheduled to receive 70 Gy in 33 fractions
with concurrent chemotherapy. Major reductions in the
primary tumor and bilateral neck nodes were observed on
the CBCT by the 12th fraction and a weight loss of w10 lb
was also observed, prompting a resimulation and new plan
generation. DIR was conducted between the initial TPCT

Example online adaptive workflow actions and potential corresponding staff roles
Action

Therapist

Acquire setup imaging and align
patient
Critical structure recontouring
Gross tumor volume contour, as
needed
Create derived contour structures
Preadaptation evaluation
Plan reoptimization
Plan evaluation
Quality assurance checks
Configuration of gating and
beam-on

C

C

Dosimetrist

Physicist

Physician

U

U

C

C

U

U

U

C

C

C

U

U

U

C

C

C

U

U

U

C

C

U

U

U

C

Performed by
Reviewed by
Roles may be adjusted based on internal credentialing processes.

U
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clinical trials, more rigid criteria are required, such as
defining a predetermined timepoint (eg, after an initial dose
or specific fraction57) or using a geometric constraint (ie,
for a head and neck trial when GTV shrinkage exceeded
2 mm via weekly imaging).58 The offline directive should
include the adaptive criteria, dose limits of the plan summation (either rigid or deformable as validated by the
physics team), and physician approval of the final plan.

Efficiency Recommendations
Frequency of plan adaptation

Fig. 3. Patient with stage III cT3N2cM0 nasopharyngeal
carcinoma who underwent an offline adaptive replan due to
volume reductions in the primary tumor and bilateral neck
nodes. (A) Initial planning computed tomography (CT)
scan at the level of the maximum extent of the primary
nasopharyngeal cancer; (B) resimulation CT scan at fraction 12 showing a major reduction in the primary tumor
volume, with the original extent of the primary tumor in
red; (C) resultant deformation map at the level of the primary tumor; (D) initial planning CT scan at the level of the
neck nodes; (E) resimulation CT scan (fraction 12) at the
level of the neck nodes showing the original extent of the
neck nodes outside of the external anatomy; and (F)
resultant deformation map at the level of the neck nodes.
Scale shown is the 3D vector displacement in millimeters.
(A color version of this figure is available at https://doi.org/
10.1016/j.ijrobp.2020.10.021.)
and the resimulation CT using a Demons-based algorithm
(SmartAdapt, version 13.0, Varian Medial Systems). Local
regions of deformation and tumor regression can be
observed.
In offline ART settings, requests are often made ad hoc
by the physician and documented in the electronic chart.
However, to implement offline ART more systematically in

In an ART workflow, the frequency of plan adaptation can
have many practical and dosimetric ramifications. In principle, increasing the frequency with which plans are
adapted to changes in patient position, anatomy, and dose
will maintain or improve the clinical goals of treatment,
including the therapeutic ratio. However, the dosimetric
improvementdand therefore the cost-benefit ratiodof
increasingly frequent adaptation is dependent on the clinical context and may exhibit diminishing returns.101 Specifically, increasing the frequency of adaptation when
OARs are anatomically stable and tumor response occurs
during the course of weeks may result in a decreasing incremental benefit and increasing use of clinical resources,
as has been demonstrated in lung cancer treatment planning
studies.3 In contrast, daily online adaptation has been
shown in a prospective clinical trial to allow substantial
simultaneous dose escalation and OAR sparing for
abdominal SBRT, in which daily anatomic variation both in
tumor and OAR anatomy is present.4 The optimal timing
and frequency of adaptation therefore depends on anatomic
changes characteristic of the treatment site, the time interval of anatomic change, and the proximity of a given target
or an OAR to a steep dose gradient. These factors, in
conjunction with the increased workload of repeating plan
preparation steps such as contouring, optimization, and
verification, affect the optimal frequency of ART. In the
context of clinical trial implementation, it is important to
clarify the specific goal of adaptation, with objective action
thresholds to allow multi-institutional uniformity of the
adaptive technique. For example, if anatomic change results
in violation of a previously defined OAR constraint or
coverage goal, adaptive replanning may be objectively
warranted.

Offline optimization and replanning
For disease sites in which anatomic changes occur gradually (over the course of several treatment fractions), offline
optimization is generally preferred to online ART owing to
greater flexibility in time constraints and less required
personnel. Definitive head and neck radiation therapy is a
scenario in which the anatomy exhibits small changes that
trend during the course of treatment. Examples include the
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Fig. 4. An example of initial (left) and adaptive (right) radiation therapy treatment plans from RTOG 1106. The initial plan
was based on pretreatment positron emission tomography (PET) and computed tomography (CT) target volumes and treated
to 46.2 Gy in 21 fractions (Fx). The adaptive plan was designed to boost the residual CT and PET volumes based on duringtreatment imaging. The boost dose was prescribed up to 3.8 Gy/Fx, limited by normal tissue constraints. PET volumes were
based on autothresholding, and dose summation was performed on the initial planning CT using rigid registration.
Figure credit: Martha Matuszak, PhD. Abbreviations: GTV Z gross tumor volume; PTV Z planning target volume.

decrease in volume and movement toward the midline of
head and neck tumors.5 This pattern of change suggests that
an ART workflow focused on occasional offline adjustments in response to the observed anatomic trends is
appropriate, but it must be based on objective criteria of
decreased target coverage or clinically impactful increases
in OAR dose. Offline ART is also appropriate when the
adaptation is determined based on imaging findings that are
available sufficiently in advance of the planned adaptation.
This generally is the case when adaptation is based on
planned interim imaging assessments, as was performed in
the RTOG 1106 trial using FDG-PET/CTebased adaptation for lung cancer as shown in Figure 4.

fraction, all of which may significantly affect the delivered
dose and associated toxicity risk.8

Example ART implementation for cancer sites
Appendix E1 highlights key evidence outlining the potential clinical benefits for major cancer disease sites. Considerations were given for online, offline, prospective, and
retrospective trials with clinical and dosimetric endpoints
summarized.

Specialty ART planning considerations
Online optimization and replanning
Online ART offers greater theoretical benefit for clinical
scenarios in which significant random interfraction
anatomic change occurs, in particular when the change
corresponds to a region with a steep dose gradient. In
prostate radiation therapy, large random changes such as
bladder and rectal filling can affect the delivered dose.
Because of the random nature of these changes, online
corrections may be more appropriate for maintaining the
desired dose distribution than offline corrections intended
to address trending changes.6,7 Furthermore, intrafractional
changes may occur on the timescale of an individual
treatment fraction, so the duration of the imaging and
replanning effort is of particular concern. A potential
benefit of online ART has also been suggested for
abdominal SBRT, which provides a similar clinical scenario
of random interfractional changes, including variable OAR
position along a high-dose gradient and high dose per

Proton therapy
Because of the sensitivity of protons to interfractional uncertainties relative to that of photons, ART is particularly
advantageous for proton therapy. In a retrospective study of
advanced non-small cell lung cancer, 61% of patients
replanned with intensity modulated proton therapy would
have required adaptation during treatment owing to
anatomic changes.102 For online adaptive proton therapy,
CBCT has been implemented with postprocessing corrections to correct for the Hounsfield numbers because small
inaccuracies may lead to large-range uncertainties.103 An
ART proton therapy workflow has been described that
generates a virtual CT scan (derived from CBCT coupled
with DIR) to produce more accurate CT numbers and
improved image quality for replanning.104 Mobile helical
CT has also been implemented for online ART proton
planning to produce high-quality data sets in the ART
process.105 Further reduction of the range uncertainty is
currently being investigated at multiple institutions,106 but
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as of yet, they do not appear to be available in the treatment
room, which will only permit offline adaptive regimens.

treatment course. In contrast, adaptive isotoxic treatment
also allows treatment modification for a given patient due
to anatomic changes that occur on an interfraction or
intrafraction basis.
Adaptive isotoxic treatment planning has several implications that must be accounted for in the context of clinical
trial implementation. First, the maximum dose believed to
be of clinical benefit should be determined a priori to
prevent adaptive delivery of a higher target dose than is
clinically warranted when OAR anatomy is favorable.
Similarly, if the relationship between target and OAR
anatomy is unfavorable, investigators must decide whether
a sacrifice in target coverage is truly warranted to maintain
OAR isotoxicity.
In the absence of ART, application of an initial treatment
plan to variable patient anatomy is known to frequently
result in a dose to OARs that violates traditional hard
planning constraints.112 Although ART reoptimization may
be performed to avoid violation of constraints, previously
established dose constraints in the nonadaptive setting may
not accurately reflect true OAR tolerance. Because previously established constraints are based on static OAR
anatomy, it is plausible that such toxicity metrics did not
account for drift of OARs into a high-dose region unknown
to the clinician. Such variability may be accounted for with
current ART techniques. Therefore, in the context of clinical trial implementation, the delivered dose to OARs with
isotoxic planning should be carefully documented so that
clinical toxicity rates observed with isotoxic ART may be
verified relative to prior expected values. In addition, online
adaptive therapy allows the potential to explore multiple
novel facets of dose delivery, including daily alterations in
dose per fraction, daily changes in dose homogeneity, and
daily dose escalation or de-escalation.

Brachytherapy
Brachytherapy is perhaps one of the most conformal and
adaptive approaches to deliver dose to a defined target.
With the advent of the GEC ESTRO guidelines107 outlining
the definition of a GTV, high-risk CTV, and intermediaterisk CTV on MRI at the time of cervical brachytherapy,
as well as the recent ICRU 69 Report108 further elaborating
on volumetric brachytherapy, we have moved from filmbased point dosimetry to volume-based brachytherapy for
both the targets and the adjacent OARs. Brachytherapy is
now referred to as image guided adaptive brachytherapy.109
With the advent of CT and MR-compatible applicators as
well as sophisticated 3D digital images, radiation plans can
be generated on these images with the applicators in place.
This reveals the doses to key volumes of these targets as
well as the OARs so that modifications can be made to
enhance target coverage and decrease dose to the critical
organs. Manipulation of dwell times and positions and use
of interstitial and intracavitary applicators can be done for
each fraction to optimally balance these competing dose
constraints. Given that usually 4 to 5 fractions are delivered
for cervical cancer, each implant offers a new opportunity
to adapt the dose distribution. This has led to a decrease in
complications and an increase in both local control and
survival that parallel and exceed the impact of concurrent
chemotherapy.109-111 Combining the doses delivered with
external beam and brachytherapy remains a challenge, and
a dedicated working group has been formed at NRG to
address this topic. Current state of the art uses an EQD2
worksheet (downloadable at:
https://www.americanbrachytherapy.org/ABS/assets/file/
public/consensus-statements/gyn_HDR_BT_docu_sheets.
xls), which converts both the brachytherapy and external
beam doses to equivalent 2 Gy doses for dose summation.
Ideally, voxel-by-voxel dose accumulation of the external
beam and brachytherapy components of treatment would be
implemented; however, these are currently works in
progress.

Forward-Looking Statements and Unmet Needs
Isotoxic dose escalation
Isotoxic-based radiation therapy refers to treatment planning that is driven primarily by the acceptable clinical
toxicity risk rather than a mandated target dose. For isotoxic planning, the target dose is escalated or de-escalated
to maintain a constant, acceptable risk of clinical toxicity
based on the dose to OARs. Isotoxic planning is not new,
with prior implementations described for multiple disease
sites including lung, prostate, and liver malignancies.2-4
Prior reports of isotoxic planning are driven by interpatient variability assumed to remain stable during a

Biological or functional guided ART
Traditional treatment response assessment based on tumor
size and anatomic change is not always timely and does not
necessarily correlate with final treatment outcome. Changes
at the physiologic and molecular levels characterize the true
underlying biological response to radiation treatment and
usually occur much earlier than detectable morphologic
changes. Therefore, imaging biomarkers hold great promises for adaptive radiation therapy, wherein the treatment
plan can be adjusted during therapy based on individual
patient’s biological response. Recent studies have shown
promising results of monitoring tumor biological and
functional changes using the image guidance system of
radiation therapy treatment machines for potential biological image guided ART.1,113 Recently, a prototype PET
scanner coupled with a linac (RefleXion, Hayward, CA)
was introduced to conduct biologically adapted radiation
therapy,114 offering potential for PET-guided online ART in
the future.115 To deploy these advanced techniques in
clinical trials, a few key challenges need to be overcome.
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Standardization of imaging acquisition protocols, measurement, and analysis methods is essential for reproducible and consistent assessment of treatment response among
multiple institutions. A rigorous QA program needs to be
established to allow for accurate quantification with sufficient validation. Most importantly, strategies and methods
for incorporating biological information into decisionmaking of treatment planning need to be developed.

Integration of advanced computing
Several advancements in computing and programming offer
strong potential to make both online and offline ART more
efficient. One such example is the integration of a graphics
processing unit that enables high processing efficiency and
yields accelerated processing speeds for radiation therapy
tasks at a relatively low cost.116-118 Many vendors have
integrated graphics processing units into their clinical
software solutions, often for dose calculation and treatment
planning. Current major unmet needs in the online ART
workflow include rapid delineation and replanning that may
be improved by the integration of deep or machine learning
techniques into the workflow. For example, a convolutional
neural network deep learning model was trained in w12
hours using 100 patient abdominal data sets for online MRguided ART, generating contours in w5 seconds with good
overall accuracy.119 Deep and machine learning offer great
potential for several other ART tasks, such as automating
treatment planning via accurate dose distributions, generating high-quality planning data sets for accurate dose
calculation,120,121 and performing automated plan quality
evaluation.122

Clinical trial integration
When incorporating ART into clinical trial design, the role
of ART as a primary or secondary trial endpoint should be
clearly defined. When characterization of ART benefit is a
primary endpoint, the trial will generally be designed to
report outcomes (1) from a population treated exclusively
with ART in a phase 1/2 manner with descriptive clinical
and toxicity outcomes or (2) in a randomized phase 2/3
setting with patients either receiving or not receiving ART
based on trial randomization, with direct comparison between trial arms. Given that online ART in particular is a
relatively new approach, to facilitate more rapid evaluation
of ART, it may often be more feasible to incorporate ART
as a secondary trial endpoint. As a secondary endpoint,
ART may be incorporated or allowed for a broad spectrum
of trials, in which ancillary data may be generated to
characterize ART benefits in the context of a nonadaptive
primary study question. For such secondary integration, use
and allowance of ART is similar in concept to current trial
designs, which often allow for variable planning techniques
including 3D, IMRT, or proton-based treatment, depending
on institutional preference.
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For any trial in which ART is a primary or secondary
endpoint, objective criteria that determine the specific action threshold to trigger an ART intervention are mandatory
to ensure treatment uniformity. Such thresholds may be
based on observed violations of initial study constraints
during the ART evaluation or a prespecified improvement
in target or OAR dose resulting from ART that is deemed to
be clinically significant. An alternative clinical trial strategy
that may implement ART as the stratification approach is to
apply ART for each treatment fraction in a manner that has
been reported in the literature.20,62,100 Another important
consideration is the extent of plan review performed for
ART. One institution evaluated its clinical practice of
having the physicians and physicists perform a visual
assessment of daily MR images without a full dose prediction for 7 pancreas patients (35 data sets) to determine
the need for daily ART.123 Importantly, a more thorough
offline dosimetric analysis revealed that daily image review
was not reliable and was insufficient to determine the
benefit of ART for a patient; visual assessment only
resulted in 14 of 35 fractions undergoing ART whereas 25
of 35 were revealed to have potential clinical benefit. Thus,
it is recommended in an online ART clinical trial setting
that daily contouring and dose prediction with a full dosimetric evaluation be performed with the appropriate time
allocated for a safe and effective implementation of this
process.
Given that noncompliance with radiation therapy protocol guidelines is known to correlate with inferior clinical
outcomes,124 it is imperative to verify that both physician
recontouring and adaptive plan quality are in accordance
with protocol recommendations. The uniformity of physician recontouring may be particularly challenging if imaging obtained for adaptive replanning does not clearly
differentiate the extent of tumor response or of residual
subclinical disease. Although protocol-mandated central
review of physician contours and the treatment plan are
widely implemented in current trials, such central review is
not feasible for online ART due to the immediate nature of
plan adaptation. Potential alternatives may be to develop a
site-specific delineation atlas using the ART imaging modality or to require initial delineation cases for physician
benchmarking. It is also recommended that a process be
incorporated in the clinical trial design that before patient
enrollment, in addition to physics and machine credentialing, institutional ART workflow will be confirmed. Such a
process will confirm appropriate departmental workflow as
per the personnel requirements section, with central review
of the first ART case to include physician recontouring,
adaptive planning, and appropriate evaluation regarding the
clinical indication for adaptive treatment. It is also recommended that the initial (minimum 3) clinical adaptive
cases for a new institution be retrospectively reviewed
centrally after each adaptive fraction to ensure adherence to
protocol.
Different adaptive strategies are appropriate for
different treatment sites due to site-specific adaptive
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radiation therapy goals and tumor and OAR characteristics. Recommendations on the range of possible adaptive
frequencies and timing can be established based on estimates of inter- and intrafractional motion and their dosimetric impact.9 For example, plan adaptations could be
triggered when the volume of the target has changed by a
prespecified action threshold or when dose to an OAR
exceeds a tolerance level. Such action thresholds may
often be defined by the baseline coverage and OARsparing goals of the trial. Recommendations can also
take the form of action levels based on assessments made
at predetermined time points or intervals (eg, based on a
single interval FDG-PET/CT as assessed in the RTOG
1106 trial or on more frequent intervals). Regardless of
the details of a particular ART workflow, the timing and
frequency of adaptation should balance objectively the
clinical value added to the patient with considerations of
the finite resources of the clinic. A template for clinical
trial language supporting an online ART workflow has
been provided in Appendix E2, including considerations
for IGRT, daily adaptation, and ART-related QA that
would be added to standard treatment planning and credentialing protocols for new clinical trials.

8. Schwartz DL, Garden AS, Thomas J, et al. Adaptive radiotherapy for
head-and-neck cancer: Initial clinical outcomes from a prospective
trial. Int J Radiat Oncol Biol Phys 2012;83:986-993.
9. Li X, Quan EM, Li Y, et al. A fully automated method for CT-onrails-guided online adaptive planning for prostate cancer intensity
modulated radiation therapy. Int J Radiat Oncol Biol Phys 2013;86:
835-841.
10. Ahunbay EE, Peng C, Godley A, et al. An on-line replanning method
for head and neck adaptive radiotherapy. Med Phys 2009;36:47764790.
11. Henke L, Kashani R, Robinson C, et al. Phase I trial of stereotactic
MR-guided online adaptive radiation therapy (SMART) for the
treatment of oligometastatic or unresectable primary malignancies of
the abdomen. Radiother Oncol 2018;126:519-526.
12. El-Bared N, Portelance L, Spieler BO, et al. Dosimetric benefits and
practical pitfalls of daily online adaptive MRI-guided stereotactic
radiation therapy for pancreatic cancer. Pract Radiat Oncol 2019;9:
e46-e54.
13. Li XA, Liu F, Tai A, et al. Development of an online adaptive solution to account for inter-and intra-fractional variations. Radiother
Oncol 2011;100:370-374.
14. Liu F, Erickson B, Peng C, Li XA. Characterization and management
of interfractional anatomic changes for pancreatic cancer radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:e423-e429.
15. Court LE, Dong L, Lee AK, et al. An automatic CT-guided adaptive
radiation therapy technique by online modification of multileaf
collimator leaf positions for prostate cancer. Int J Radiat Oncol Biol
Phys 2005;62:154-163.
16. Ahunbay EE, Peng C, Holmes S, et al. Online adaptive replanning
method for prostate radiotherapy. Int J Radiat Oncol Biol Phys 2010;
77:1561-1572.
17. Mohan R, Zhang X, Wang H, et al. Use of deformed intensity distributions for on-line modification of image-guided IMRT to account
for interfractional anatomic changes. Int J Radiat Oncol Biol Phys
2005;61:1258-1266.
18. Heijkoop ST, Langerak TR, Quint S, et al. Clinical implementation
of an online adaptive plan-of-the-day protocol for nonrigid motion
management in locally advanced cervical cancer IMRT. Int J Radiat
Oncol Biol Phys 2014;90:673-679.
19. Henke LE, Olsen JR, Contreras JA, et al. Stereotactic MR-guided
online adaptive radiation therapy (SMART) for ultracentral thorax
malignancies: Results of a phase 1 trial. Adv Radiat Oncol 2019;4:
201-209.
20. Bruynzeel AM, Tetar SU, Oei SS, et al. A prospective single-arm
phase 2 study of stereotactic magnetic resonance guided adaptive
radiation therapy for prostate cancer: Early toxicity results. Int J
Radiat Oncol Biol Phys 2019;105:1086-1094.
21. US National Library of Medicine. NCT03621644. Stereotactic MRIguided On-table Adaptive Radiation Therapy (SMART) for locally
advanced pancreatic cancer. Available at: https://clinicaltrials.gov/
ct2/show/NCT03621644. Accessed October 29, 2020.
22. Hiraoka M, Matsuo Y, Sawada A, et al. Realization of dynamic tumor
tracking irradiation with real-time monitoring in lung tumor patients
using a gimbaled x-ray head radiation therapy equipment. Int J
Radiat Oncol Biol Phys 2012;84:S560-S561.
23. Pathmanathan AU, van As NJ, Kerkmeijer LGW, et al. Magnetic
resonance imaging-guided adaptive radiation therapy: A “game
changer” for prostate treatment? Int J Radiat Oncol Biol Phys 2018;
100:361-373.
24. Kontaxis C, Bol G, Stemkens B, et al. Towards fast online intrafraction replanning for free-breathing stereotactic body radiation
therapy with the MR-linac. Phys Med Biol 2017;62:7233.
25. Klawikowski S, Tai A, Ates O, et al. A fast 4D IMRT/VMAT
planning method based on segment aperture morphing. Med Phys
2018;45:1594-1602.
26. Hara W, Soltys SG, Gibbs IC. CyberKnife robotic radiosurgery
system for tumor treatment. Expert Rev Anticancer Ther 2007;7:
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Conclusions
Overall, although resource intensive, ART shows incredible
promise for offering gains in OAR sparing and improving
target coverage. As vendor offerings increase and our
ability to perform workflows within standard clinical
operation becomes easier, the likelihood of implementing
ART more routinelydwhen clinically indicateddis rapidly
expanding.
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